-
公开(公告)号：EP2391712A1
公开(公告)日：2011-12-07
申请号：EP10702657.7
申请日：2010-01-29
申请人： Universite De La Mediterranee , INSERM - Institut National de la Santé et de la Recherche Médicale
发明人： BLOT-CHABAUD, Marcel , HARHOURI, Karim , BARDIN, Nathalie , GUILLET, Benjamin , DIGNAT-GEORGE, Françoise
IPC分类号： C12N5/071
CPC分类号： C07K16/3092 , A61K38/00 , C07K14/70503
摘要： The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both nature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
-
公开(公告)号：EP3244909B1
公开(公告)日：2019-10-09
申请号：EP16700619.6
申请日：2016-01-14
申请人： Université d'Aix-Marseille , Assistance Publique Hôpitaux de Marseille , INSERM (Institut National de la Santé et de la Recherche Médicale) , Association Francaise Contre Les Myopathies , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS , Progelife
-
3.发明公开PROTEASOME INHIBITORS FOR TREATING A DISORDER RELATED TO AN ACCUMULATION OF NON-DEGRADED ABNORMAL PROTEIN OR A CANCER 审中-公开蛋白酶抑制剂用于治疗与非降解的异常蛋白质或癌症累积有关的疾病
公开(公告)号：EP3244909A1
公开(公告)日：2017-11-22
申请号：EP16700619.6
申请日：2016-01-14
申请人： Université d'Aix Marseille , Assistance Publique Hôpitaux de Marseille , INSERM - Institut National de la Santé et de la Recherche Médicale , Association Francaise Contre Les Myopathies , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- , Progelife
发明人： LEVY, Nicolas , CAU, Pierre , DE SANDRE-GIOVANNOLI, Annachiara , HARHOURI, Karim , PERRIN, Sophie , NAVARRO, Claire , CHARTIER, Aymeric , SIMONELIG, Martine
摘要： The invention relates to a proteasome inhibitor for use for treating and/or preventing a disorder related to an accumulation of a non-degraded abnormal protein, particularly a premature ageing disorder. The invention also relates to the use of proteasome inhibitors for attenuating physiological ageing. The invention also relates to the use of proteasome inhibitors in the treatment and/or prevention of age-related disorders and their metabolic consequences. The invention also relates to the dermato logical, dermo cosmetic or cosmetic use of a proteasome inhibitor for preventing and/or attenuating skin ageing. The invention also relates to the use of proteasome inhibitors in the treatment of cancer.
-
公开(公告)号：EP2391712B1
公开(公告)日：2016-03-30
申请号：EP10702657.7
申请日：2010-01-29
申请人： Université d'Aix-Marseille , INSERM - Institut National de la Santé et de la Recherche Médicale
发明人： BLOT-CHABAUD, Marcel , HARHOURI, Karim , BARDIN, Nathalie , GUILLET, Benjamin , DIGNAT-GEORGE, Françoise
IPC分类号： C12N5/071
CPC分类号： C07K16/3092 , A61K38/00 , C07K14/70503
摘要： The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both nature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
